PCM
FRTX

Prelude Capital Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Prelude Capital Management’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-5
Closed -$16K – 2210
2014
Q3 		$16K Sell
5
-5
-50% -$19.4K ﹤0.01% 1755
2014
Q2 		$38K Buy
+10
New +$37.6K 0.01% 1518

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $2.46B AUM 57.16% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SAIG
Semper Augustus Investments Group Highlands Ranch, Colorado $837M AUM 42.35% 1-Year Est. Return

Prelude Capital Management's FRTX Position: Q4 2014 in Review

Prelude Capital Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2014, closing a stake of 5 shares — an estimated $16K sold.

Prelude Capital Management first reported a position in FRTX in Q2 2014 and held it in 2 quarters. The position peaked at $38K in Q2 2014. 64 funds tracked by Wall St. Rank hold FRTX as of Q4 2014.

  • Prelude Capital Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Prelude Capital Management sold 5 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2014, an estimated $16K.
  • Prelude Capital Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2014 and held it in 2 quarters.
  • Prelude Capital Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $38K in Q2 2014.
  • 64 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2014.

Based on Prelude Capital Management's 13F filing for Q4 2014, filed 13 Feb 2015.